Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics

Oncternal Therapeutics, Inc. (ONCT): $8.10

0.10 (+1.25%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ONCT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#105 of 362

in industry

ONCT Price/Volume Stats

Current price $8.10 52-week high $13.14
Prev. close $8.00 52-week low $5.57
Day low $8.03 Volume 2,500
Day high $8.15 Avg. volume 9,891
50-day MA $8.66 Dividend yield N/A
200-day MA $8.01 Market Cap 23.98M

ONCT Stock Price Chart Interactive Chart >


Oncternal Therapeutics, Inc. (ONCT) Company Bio


Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.


ONCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCT Latest Social Stream


Loading social stream, please wait...

View Full ONCT Social Stream

Latest ONCT News From Around the Web

Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

William White on InvestorPlace | December 12, 2023

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

Yahoo | November 11, 2023

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR

Yahoo | November 9, 2023

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li

Yahoo | November 2, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer

Yahoo | October 26, 2023

Read More 'ONCT' Stories Here

ONCT Price Returns

1-mo -10.00%
3-mo -1.46%
6-mo -32.27%
1-year 9.43%
3-year -92.20%
5-year -94.05%
YTD -24.47%
2023 -46.38%
2022 -55.95%
2021 -53.67%
2020 24.05%
2019 -27.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!